Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

405 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine.
Afferi L, Spahn M, Hayoz S, Strebel RT, Rothschild SI, Seifert H, Özdemir BC, Kiss B, Maletzki P, Engeler D, Wirth G, Hadaschik B, Lucca I, John H, Sauer A, Müntener M, Bubendorf L, Schneider M, Musilova J, Petrausch U, Cathomas R; Swiss Group for Clinical Cancer Research (SAKK). Afferi L, et al. Among authors: hadaschik b. BJU Int. 2024 Mar 8. doi: 10.1111/bju.16318. Online ahead of print. BJU Int. 2024. PMID: 38456541
Prognostic Implications of 68Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid Tumors.
Watanabe M, Fendler WP, Grafe H, Hirmas N, Hamacher R, Lanzafame H, Pabst KM, Hautzel H, Aigner C, Kasper S, von Tresckow B, Stuschke M, Kümmel S, Lugnier C, Hadaschik B, Grünwald V, Zarrad F, Siveke JT, Herrmann K, Weber M. Watanabe M, et al. Among authors: hadaschik b. J Nucl Med. 2024 May 23:jnumed.123.266981. doi: 10.2967/jnumed.123.266981. Online ahead of print. J Nucl Med. 2024. PMID: 38782454
Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial.
Krilaviciute A, Kaaks R, Seibold P, de Vrieze M, Lakes J, Radtke JP, Kuczyk M, Harke NN, Debus J, Fink CA, Herkommer K, Gschwend JE, Meissner VH, Benner A, Kristiansen G, Hadaschik B, Arsov C, Schimmöller L, Antoch G, Giesel FL, Makowski M, Wacker F, Schlemmer HP, Becker N, Albers P. Krilaviciute A, et al. Among authors: hadaschik b. Eur Urol. 2024 May 15:S0302-2838(24)02358-3. doi: 10.1016/j.eururo.2024.04.030. Online ahead of print. Eur Urol. 2024. PMID: 38749854 Free article.
Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review.
Gartrell BA, Phalguni A, Bajko P, Mundle SD, McCarthy SA, Brookman-May SD, De Solda F, Jain R, Yu Ko W, Ploussard G, Hadaschik B. Gartrell BA, et al. Among authors: hadaschik b. Eur Urol Oncol. 2024 May 13:S2588-9311(24)00106-8. doi: 10.1016/j.euo.2024.04.016. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38744587 Free article. Review.
Safety and Efficacy of Extended Therapy with [177Lu]Lu-PSMA: A German Multicenter Study.
Seifert R, Telli T, Lapa C, Desaulniers M, Hekimsoy T, Weber WA, Pfob C, Hadaschik B, Bögemann M, Schäfers M, Herrmann K, Rahbar K, Eiber M, Fendler WP. Seifert R, et al. Among authors: hadaschik b. J Nucl Med. 2024 May 2:jnumed.123.267321. doi: 10.2967/jnumed.123.267321. Online ahead of print. J Nucl Med. 2024. PMID: 38697669
Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study.
Flippot R, Telli T, Velev M, Fléchon A, De Vries-Brilland M, Turpin L, Bergman A, Turco F, Mahammedi H, Fendler WP, Giraudet AL, Josset Q, Montravers F, Vogel W, Gillessen S, Berardi Vilei S, Herrmann K, Kryza D, Paone G, Hadaschik B, Merlin C, Dufour PA, Bernard-Tessier A, Naoun N, Patrikidou A, Garcia C, Foulon S, Pagès A, Fizazi K. Flippot R, et al. Among authors: hadaschik b. Eur Urol Oncol. 2024 Apr 24:S2588-9311(24)00094-4. doi: 10.1016/j.euo.2024.03.013. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38664139
Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).
Nikitas J, Lam E, Booker KA, Fendler WP, Eiber M, Hadaschik B, Herrmann K, Hirmas N, Lanzafame H, Stuschke M, Czernin J, Steinberg ML, Nickols NG, Kishan AU, Calais J. Nikitas J, et al. Among authors: hadaschik b. J Nucl Med. 2024 Apr 25:jnumed.123.267004. doi: 10.2967/jnumed.123.267004. Online ahead of print. J Nucl Med. 2024. PMID: 38664019
405 results